Status:
COMPLETED
PORTHOS - PORTuguese Heart Failure Observational Study
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
Sociedade Portuguesa de Cardiologia
NOVA Medical School
Conditions:
Heart Failure
Eligibility:
All Genders
50+ years
Brief Summary
This study aims to determine the prevalence of heart failure in the resident population in mainland Portugal aged 50 years or above, using a contemporary, guideline-based diagnostic approach, to optim...
Detailed Description
The contemporary prevalence of heart failure in Portugal is largely unknown and may differ from that reported in early studies, which were conducted in the late 1990s-early 2000s with the diagnostic t...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Community-dwelling citizens living in Mainland Portugal;
- Registration in a primary care centre;
- Age ≥50 years at recruitment;
- Voluntary signed informed consent.
- Exclusion criteria:
- Living in institutions (e.g., nursing homes, prisons, military facilities, hospitals);
- Non-Portuguese speakers;
- Reduced physical and/or cognitive ability hampering participation (e.g., blindness, deafness, or cognitive impairment).
Exclusion
Key Trial Info
Start Date :
June 30 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 18 2023
Estimated Enrollment :
6189 Patients enrolled
Trial Details
Trial ID
NCT05434923
Start Date
June 30 2022
End Date
September 18 2023
Last Update
August 26 2024
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Aljustrel, Portugal
2
Research Site
Aveiro, Portugal
3
Research Site
Braga, Portugal
4
Research Site
Castelo Branco, Portugal